BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37600823)

  • 21. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
    McDonald GB; Freston JW; Boyer JL; DeLeve LD
    Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
    Pennesi E; Michels N; Brivio E; van der Velden VHJ; Jiang Y; Thano A; Ammerlaan AJC; Boer JM; Beverloo HB; Sleight B; Chen Y; Vormoor-Bürger B; Rives S; Bielorai B; Rössig C; Petit A; Rizzari C; Engstler G; Starý J; Bautista Sirvent FJ; Chen-Santel C; Bruno B; Bertrand Y; Rialland F; Plat G; Reinhardt D; Vinti L; Von Stackelberg A; Locatelli F; Zwaan CM
    Leukemia; 2022 Jun; 36(6):1516-1524. PubMed ID: 35468945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
    Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
    Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
    [TBL] [Abstract][Full Text] [Related]